Glenmark Pharmaceuticals Expands Its Portfolio with New Phytonadione Injectable Emulsion Launch
Glenmark Pharmaceuticals Launches Phytonadione Injectable Emulsion
Glenmark Pharmaceuticals Inc., USA, recently announced the release of its latest product, Phytonadione Injectable Emulsion USP, with a concentration of 10 mg/mL single-dose ampules. This innovative solution is designed to provide healthcare professionals with an effective therapeutic option for patients in need of Vitamin K supplementations.
The Phytonadione Injectable Emulsion by Glenmark is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, manufactured by Hospira, Inc.. According to sales data from IQVIA™, the Vitamin K1 Injectable Emulsion market reached approximately $19.7 million in annual sales by November 2024. This clearly illustrates the demand and importance of such pharmaceuticals in healthcare.
A Commitment to Quality and Affordability
Marc Kikuchi, President and Business Head for North America at Glenmark, expressed enthusiasm about this new product launch. He stated, “We are excited to announce the launch of Phytonadione Injectable Emulsion USP. This addition not only broadens our portfolio in the institutional channel but also reinforces our commitment to delivering high-quality, affordable alternatives for patients.” This sentiment highlights Glenmark's ongoing mission to support healthcare providers and contribute positively to patient outcomes.
Glenmark Pharmaceuticals is known for its extensive research and development efforts, focusing on various therapeutic areas such as respiratory, dermatology, and oncology. The company operates 11 world-class manufacturing facilities across four continents and has a product presence in more than 80 countries. With this new product launch, Glenmark aims to further establish itself as a leader in the pharmaceutical industry.
Recognition and Commitment to Sustainability
In recent years, Glenmark has received significant recognition for its advancements in the pharmaceutical sector. In 2022, it was ranked among the Top 100 Companies by In Vivo/Scrip 100 based on R&D and pharmaceutical sales. Moreover, Glenmark's commitment to sustainability is evident, as it has recently gained approval for its Greenhouse Gas (GHG) emission reduction targets from the Science Based Target initiative (SBTi), marking a considerable step towards environmental responsibility in pharmaceutical manufacture.
The company has also made impactful strides through its Corporate Social Responsibility (CSR) initiatives, reportedly improving the lives of over 3 million individuals within the past decade.
Final Thoughts
As Glenmark Pharmaceuticals continues to innovate and expand its product offerings, the launch of Phytonadione Injectable Emulsion USP stands as a testament to its commitment to quality healthcare solutions and patient-centered care. This product not only enhances the company’s portfolio but also serves as a vital resource for healthcare providers looking for effective treatments. For more information about Glenmark and its comprehensive product range, please visit Glenmark Pharmaceuticals.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.